Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Early insulin treatment in type 2 diabetes

  2013cited by this paper
• Radioligand binding methods for membrane preparations and intact cells.

  2011cited by this paper
• Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function

  2011cited by this paper
• The early endosome: a busy sorting station for proteins at the crossroads.

  2010cited by this paper
• Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function.

  2010cited by this paper
• Glucagon and glucagon-like peptides 1 and 2.

  2010cited by this paper
• The evolving place of incretin-based therapies in type 2 diabetes

  2010influential reference
• N-Glycosylation plays a role in protein folding of human UGT1A9.

  2010cited by this paper
• GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.

  2010cited by this paper
• Environmental Transition of Signal-Anchor Sequences during Membrane Insertion via the Endoplasmic Reticulum Translocon

  2010cited by this paper
• Structural determinants underlying constitutive dimerization of unoccupied human follitropin receptors.

  2010cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010influential reference
• Trafficking and signalling of gonadotrophin‐releasing hormone receptors: an automated imaging approach

  2010cited by this paper
• Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy

  2010cited by this paper
• Role of asparagine-linked glycosylation in cell surface expression and function of the human adrenocorticotropin receptor (melanocortin 2 receptor) in 293/FRT cells.

  2010cited by this paper
• Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.

  2010cited by this paper
• Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes

  2010cited by this paper
• Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.

  2010cited by this paper
• Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

  2010cited by this paper
• Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances

  2010cited by this paper
• Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

  2010cited by this paper
• Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

  2010cited by this paper
• Molecular mechanisms underlying nutrient detection by incretin-secreting cells

  2010cited by this paper
• The dipeptidyl peptidase IV family in cancer and cell biology

  2010cited by this paper
• Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study,

  2010cited by this paper
• Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery

  2010cited by this paper
• Signaling by internalized G-protein-coupled receptors.

  2010cited by this paper
• Signal peptide peptidase (SPP) assembles with substrates and misfolded membrane proteins into distinct oligomeric complexes

  2010cited by this paper
• Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor.

  2010cited by this paper
• Molecular insights into mechanisms of intramembrane proteolysis through signal peptide peptidase (SPP).

  2010cited by this paper
• The Pseudo Signal Peptide of the Corticotropin-releasing Factor Receptor Type 2a Decreases Receptor Expression and Prevents Gi-mediated Inhibition of Adenylyl Cyclase Activity*

  2010cited by this paper
• Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay

  2010cited by this paper
• Featured Insulin-like actions of glucagon-like peptide-1 : a dual receptor hypothesis

  2010cited by this paper
• Mucin‐type O‐glycosylation – putting the pieces together

  2010cited by this paper
• Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

  2010cited by this paper
• Allosteric ligands for G protein‐coupled receptors: A novel strategy with attractive therapeutic opportunities

  2010cited by this paper
• Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database

  2010cited by this paper
• Mutant proinsulin proteins associated with neonatal diabetes are retained in the endoplasmic reticulum and not efficiently secreted.

  2010cited by this paper
• Recognition of a signal peptide by the signal recognition particle

  2010cited by this paper
• G protein‐coupled receptors: the inside story

  2010cited by this paper
• Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?

  2010cited by this paper
• Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

  2010cited by this paper
• Pharmacological Characterization of Human Incretin Receptor Missense Variants

  2010cited by this paper
• The year in G protein-coupled receptor research.

  2010cited by this paper
• Peptide drugs to target G protein-coupled receptors.

  2010cited by this paper
• The incretin system and its role in type 2 diabetes mellitus.

  2009cited by this paper
• Identification of cAMP-dependent kinase as a third in vivo ribosomal protein S6 kinase in pancreatic beta-cells.

  2009cited by this paper
• μ-Opioid Receptor Cell Surface Expression Is Regulated by Its Direct Interaction with Ribophorin I

  2009cited by this paper
• Evaluation of signal peptide prediction algorithms for identification of mycobacterial signal peptides using sequence data from proteomic methods

  2009cited by this paper
• The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins

  2009cited by this paper
• A signal-anchor sequence stimulates signal recognition particle binding to ribosomes from inside the exit tunnel

  2009cited by this paper
• GPCR and G proteins: drug efficacy and activation in live cells.

  2009cited by this paper
• GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells

  2009cited by this paper
• A comprehensive assessment of N-terminal signal peptides prediction methods

  2009influential reference
• Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

  2009cited by this paper
• Early Insulin Treatment in Type 2 Diabetes

  2009cited by this paper
• Glucagon-Like Peptide-1 Agonists Protect Pancreatic β-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB

  2009cited by this paper
• Allosteric Modulators of G Protein-Coupled Receptors: Future Therapeutics for Complex Physiological Disorders

  2009influential reference
• Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

  2009cited by this paper
• Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia

  2009cited by this paper
• Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization

  2009cited by this paper
• Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor.

  2009cited by this paper
• Protein targeting by the signal recognition particle

  2009cited by this paper
• Unconventional Mechanisms of Protein Transport to the Cell Surface of Eukaryotic Cells

  2009cited by this paper
• Essentials of glycobiology

  2009influential reference
• Discovery of new GPCR biology: one receptor structure at a time.

  2009cited by this paper
• The Sequence after the Signal Peptide of the G Protein-Coupled Endothelin B Receptor Is Required for Efficient Translocon Gating at the Endoplasmic Reticulum Membrane

  2009cited by this paper
• Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling.

  2009cited by this paper
• A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism.

  2009cited by this paper
• Insulin granule biogenesis, trafficking and exocytosis.

  2009cited by this paper
• Ribosomal S6 Kinase 2 Directly Phosphorylates the 5-Hydroxytryptamine 2A (5-HT2A) Serotonin Receptor, Thereby Modulating 5-HT2A Signaling*

  2009cited by this paper
• Fate of the beta-cell in the pathophysiology of type 2 diabetes.

  2009cited by this paper
• Folding scene investigation: membrane proteins

  2009cited by this paper
• Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists

  2009cited by this paper
• Multiple conformational switches in a GTPase complex control co-translational protein targeting

  2009cited by this paper
• Overview of insulin replacement therapy.

  2009cited by this paper
• Dietary fats and prevention of type 2 diabetes.

  2009cited by this paper
• Disruption of N‐linked glycosylation enhances ubiquitin‐mediated proteasomal degradation of the human ATP‐binding cassette transporter ABCG2

  2009cited by this paper
• Targeting of inositol 1,4,5-trisphosphate receptor to the endoplasmic reticulum by its first transmembrane domain

  2009cited by this paper
• Visualization of distinct entities of the SecYEG translocon during translocation and integration of bacterial proteins.

  2009cited by this paper
• Vegetarian and vegan diets in type 2 diabetes management.

  2009cited by this paper
• Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.

  2009cited by this paper
• Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor*

  2009influential reference
• Transplantation of PC1/3-Expressing α-cells Improves Glucose Handling and Cold Tolerance in Leptin-resistant Mice.

  2009cited by this paper
• Fine-tuning of GPCR activity by receptor-interacting proteins

  2009cited by this paper
• Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists

  2009influential reference
• An efficient platform for screening expression and crystallization of glycoproteins produced in human cells

  2009cited by this paper
• Architecture, function and prediction of long signal peptides

  2009cited by this paper
• Diabetic patients: epidemiology and global impact.

  2009influential reference
• Melanocortin 5 receptor activates ERK1/2 through a PI3K-regulated signaling mechanism.

  2009cited by this paper
• ER and aging-Protein folding and the ER stress response.

  2009cited by this paper
• The effects of GLP-1 infusion in the hepatic portal region on food intake.

  2009cited by this paper
• Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.

  2009cited by this paper
• Akt and PTEN: beta-cell mass and pancreas plasticity.

  2009cited by this paper
• Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver

  2009cited by this paper
• Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

  2009influential reference
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

  2009cited by this paper
• G-protein-coupled receptor-focused drug discovery using a target class platform approach.

  2009cited by this paper

• Signalling and Regulation of the Glucagon-like Peptide-1 receptor

  2014cites this paper